Trial reportMedecine tropicale et sante internationale2026
[Evaluation of the Efficacy and Tolerance of Tranexamic Acid Combined with Inoserp
Trial report in Medecine tropicale et sante internationale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemorrhagic syndrome accounts for a significant proportion of the mortality and morbidity associated with snakebites in sub-Saharan Africa. Hyperfibrinolysis, which has been reported in some cases, suggests the potential benefit of antifibrinolytics; however, these have been little studied in this context. This study aimed to evaluate the effectiveness of combining tranexamic acid and antivenom in treating hemorrhagic syndrome and coagulopathy associated with Materials and methods: Patients presenting with hemorrhagic syndrome due to envenomation were prospectively included at the Saint Jean de Dieu Hospital in Tanguiéta, Benin. Patients were randomized into two groups: one receiving antivenom and tranexamic acid (SAV + AT) and one receiving only antivenom (SAV). All patients received two vials of Inoserp Results: Twenty-five patients were included: Twelve patients were in the SAV + AT group, and thirteen patients were in the SAV group. Six patients in the SAV + AT group and five patients in the SAV group experienced persistent or recurrent bleeding (p = 0.695). There was no significant difference in WBCT at different time points between the two groups, nor in INR at 6 and 12 hours. There were no adverse effects suggesting intolerance to tranexamic acid (e.g., ocular abnormality, convulsions, or thrombosis), and plasma creatinine levels did not differ significantly between the two groups. Conclusion: Systematic use of tranexamic acid showed no benefit for hemorrhagic syndrome and coagulopathy associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.